ArticleOncotarget2015
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05512104 (Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 Expression), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 Expression
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Non-classical immune checkpoint CD137/CD137L and CD200/CD200R expressions are regulated by the tumor immune microenvironment in lymph node aspirates from lung cancer patients.Frontiers in immunology · 2026Article
- Evaluation of CD200 marker variations and its correlation with clinicopathological features of chronic lymphocytic leukemia patients: a case-control study.Journal of hematopathology · 2025Article
- CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases.Diagnostic pathology · 2025Article
- Targeting CD200 in Breast Cancer: Opportunities and Challenges in Immunotherapeutic Strategies.International journal of molecular sciences · 2024Review
- Targeting Histone 3 Variants Epigenetic Landscape and Inhibitory Immune Checkpoints: An Option for Paediatric Brain Tumours Therapy.Current neuropharmacology · 2024Review
- Checkpoint Inhibitors in Acute Myeloid Leukemia.Biomedicines · 2023Review
- Review
- Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Article
- Targeting pediatric leukemia-propagating cells with anti-CD200 antibody therapy.Blood advances · 2021Article
- Clinical Importance of CD200 Expression in Colorectal Liver Metastasis.Annals of surgical oncology · 2021Article
- Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML.Journal for immunotherapy of cancer · 2021Article
- Impact of Concomitant Aberrant CD200 and BCL2 Overexpression on Outcome of Acute Myeloid Leukemia: A Cohort Study from a Single CenterTurkish journal of haematology : official journal of Turkish Society of Haematology · 2021Article
- CD200:CD200R Interactions and Their Importance in Immunoregulation.International journal of molecular sciences · 2021Review
- Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments.Frontiers in pharmacology · 2021Review
- CD200 expression marks leukemia stem cells in human AML.Blood advances · 2020Article
- Review
- Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.International journal of molecular sciences · 2019Review
- CD157 and CD200 at the crossroads of endothelial remodeling and immune regulation.Stem cell investigation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD200, a protein belonging to the immunoglobulin superfamily, has been associated with a poor prognosis in lymphoproliferative disorders and in acute leukemia. We studied the expression of CD200 in a series of 244 patients with diagnosis of acute myeloid leukemia (AML), to evaluate its impact on outcome and its possible association with other known prognostic factors. CD200 was found in 136/244 (56%) patients, in 41 of whom (30%) with high intensity of expression (MFI ≥ 11). CD200 was more frequent in secondary compared to de novo leukemia (p = 0.0006), in CD34 positive cases (p = 0.00001), in Bcl2 overexpressing cases (p = 0.01), in those wild-type Flt3 (p = 0.004) and with favorable or unfavorable compared to intermediate karyotype (p = 0.0003). CD200+ patients have a two-fold lower probability to attain complete remission, both in univariate (p = 0.006) and multivariate (p = 0.04) analysis. The negative impact of CD200 was found also in overall survival (p = 0.02) and was correlated with the intensity of expression of the molecule (p = 0.024). CD200 has an additive negative impact on survival in patients with unfavorable cytogenetic (p = 0.046) and in secondary leukemia (p = 0.05), and is associate with a worsening of outcome in patients with favorable biological markers, such as mutated NPM (p = 0.02), wild-type Flt3 (p = 0.034), negativity of CD34 (p = 0.03) and of CD56 (p = 0.03). In conclusion, CD200 is emerging as both a prognostic factor and a potential target of novel therapeutic approaches for AML, aiming to reverse the "do not eat me" signal of CD200 or to manipulate the suppressive immune microenvironment induced by CD200 binding to its receptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.